On March 3, 2026, the FDA announced 30 warning letters to telehealth companies over misleading marketing of compounded GLP-1 medications. Within weeks, two of the largest players — Hims and Ro — exited the compounded category entirely and moved to FDA-approved branded medication only. If you are currently on a compounded GLP-1, or considering one, here is what actually changed and what it means for you.
What happened
- •March 3, 2026: FDA issues 30 warning letters to telehealth companies over compounded-GLP-1 marketing claims
- •March 2026: Hims announces it will sell only FDA-approved branded GLP-1s
- •Through 2026: Ro follows, exiting compounded GLP-1s for brand-name-only
- •Still operating: Dozens of compounded providers continue, including Mochi Health, Eden, Henry Meds, and Cora Health
What the warning letters were actually about
The letters targeted marketing, not the medications themselves. The recurring problem was language that blurred the line between a compounded preparation and an FDA-approved product — advertising that implied equivalence to Ozempic or Wegovy, understated the regulatory status, or omitted required risk information.
That distinction is worth holding onto. This was not a finding that compounded semaglutide is dangerous. It was a finding that a lot of companies described it inaccurately.
What compounded actually means
A compounded medication is prepared by a licensed pharmacy rather than manufactured by a drug company under an FDA approval. Compounded semaglutide contains semaglutide — the same molecule as Ozempic and Wegovy — but it is not the same product.
The differences are real. FDA-approved products go through bioequivalence testing, batch release testing, stability studies, and manufacturing inspections under a defined framework. Compounded preparations do not. Potency, sterility, and stability depend on the individual compounder's practices, and those vary.
There are two categories of compounder, and the difference matters. A 503A pharmacy compounds per individual prescription under state board oversight. A 503B outsourcing facility registers with the FDA, is subject to FDA inspection, and must follow Current Good Manufacturing Practice. 503B carries substantially more oversight. Both are legal.
Four questions to ask any compounded provider
- 1. Which pharmacy fills my prescription? A provider that won't name it is preventing you from doing basic diligence.
- 2. Is it a 503A pharmacy or a 503B facility? 503B means FDA registration and inspection. Ask directly.
- 3. Is the product tested for potency and sterility? Reported adverse events have included dosing errors from concentration confusion. This is not theoretical.
- 4. What is the after-hours escalation path? Establish this before you need it, not during a bad reaction.
The affordability argument has weakened
The reason compounded GLP-1s exist is that brand-name medication was priced beyond reach — list prices above $1,000 a month put Wegovy and Zepbound out of range for anyone without coverage. Compounded semaglutide at $150 was not a preference; it was the only option.
That gap has narrowed substantially. LillyDirect now sells FDA-approved Zepbound at $299 for the 2.5 mg starting dose, $399 for 5 mg, and a flat $449 for every dose from 7.5 mg through 15 mg. Novo Nordisk operates a comparable direct channel for Wegovy.
At $449 for the actual approved product, the premium over a $200 compounded program is roughly $250 a month. That is still real money, and for many people it remains decisive. But it is a different calculation than $150 versus $1,000, and it is worth re-running if you chose compounded medication before the direct programs launched.
If you are currently on a compounded GLP-1
Do not stop abruptly out of concern about headlines. Discontinuing mid-titration brings appetite back quickly and wastes the adaptation you have built. Nothing in the March 2026 action found the medications themselves unsafe.
Do ask your provider the four questions above. If the answers are clear and the pharmacy is identifiable and licensed, continuing is reasonable. If your provider deflects, that is information — and there are dozens of compounded providers who will answer.
Bottom line
The 2026 enforcement action was about marketing accuracy, not medication safety. Compounded GLP-1s remain legal and widely available. What changed is that two major platforms left the category and manufacturer-direct pricing made FDA-approved medication affordable enough to be a genuine alternative for the first time.
Compare both routes in our compounded vs brand-name guide.